US4877778A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Method of enhancing lipophile transport using cyclodextrin derivatives
Assignee: Boston Children's Hospital
•
Filing: 1987-07-01
•
Granted: 1989-10-31
•
Expires: 2007-07-01
Abstract
Abstract Levels of cholesterol, vitamin A, triglycerides, and other lipophiles in the human circulation can be manipulated by intravenous infusion of cyclodextrin-type compounds. The cyclodextrin-type compound should be highly soluble in water, amorphous and of only moderate molecular weight in order to be easily excreted; one preferred cyclodextrin, 2-hydroxypropyl- beta -cyclodextrin with an average molecular weight of 1460, is administered at doses of 0.5 g/kg x day. The serum levels of the lipophiles indicate that the infusion may serve to mobilize the lipophile from tissues, induce its excretion, and furthermore affect its homeostasis.
Inventors
- 👤 Thomas O. Carpenter
- 👤 Josef Pitha
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-04 23:36
CPC Classifications
C; C08; C08B; C08B37/00; C08B37/0006; C08B37/0009; C08B37/0012
Claims Analysis
Total Claims: 10
Claim 1
Independent Claim
74 words
A method of treating a mammal to catalytically enhance serum transport of a naturally occurring lipophile present in prolonged excessive concentrations, comprising administering to said mammal a cyclodextrin derivative having the following formula: ##STR2## where n=1-3, and glu represents a glucose or substituted glucose residue connected in the maner of an amylose chain, each said glucose residue being independently selected from glucose and alkyl or hydroxyalkyl substituted glucose derivatives, said cyclodextrin being water soluble.
Claim 2
Independent Claim
74 words
A method of treating a mammal to catalytically enhance serum transport of a naturally occurring lipophile present in prolonged excessive concentrations, comprising administering to said mammal a cyclodextrin derivative having the following formula: ##STR2## where n=1-3, and glu represents a glucose or substituted glucose residue connected in the maner of an amylose chain, each said glucose residue being independently selected from glucose and alkyl or hydroxyalkyl substituted glucose derivatives, said cyclodextrin being water soluble.
Claim 3
Dependent Claim
13 words
The method of claim 1 wherein said method enhances serum transport of cholesterol.
Claim 4
Dependent Claim
14 words
The method of claim 1 wherein said method enhances serum transport of vitamin A.
Claim 5
Dependent Claim
13 words
The method of claim 1 wherein said method enhances serum transport of triglycerides.
Claim 6
Independent Claim
16 words
The method of any of claims 1-4 wherein said cyclodextrin derivative is administered to a human.
Claim 7
Independent Claim
13 words
The method of any of claims 1-4 wherein said cyclodextrin derivative comprises 2-hydroxypropyl-β-cyclodextrins.
Claim 8
Independent Claim
14 words
The method of any of claims 1-4 wherein said cyclodextrin derivative is administered intravenously.
Claim 9
Dependent Claim
14 words
The method of claim 7 wherein said cyclodextrin derivative is administered by intravenous infusion.
Claim 10
Independent Claim
13 words
The method of any of claims 1-4 wherein said cyclodextrin derivative is amorphous.
References Cited (Backward Citations)
US3459731A
Cited
US3453259A
Cited
JPS5731661A
Cited
EP0070368A1
Cited
US4407795A
Cited
JPS58210077A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1992-10-30 | 1993-05-01 | 1993-10-31 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1996-10-30 | 1997-05-01 | 1997-10-31 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2000-10-30 | 2001-05-01 | 2001-10-31 | $7700.00 | Window Closed / Lapsed |